Indivior PLC (LON:INDV – Get Free Report) shares traded down 15.7% on Thursday . The stock traded as low as GBX 548.71 ($6.93) and last traded at GBX 732 ($9.25). 1,888,371 shares traded hands during trading, an increase of 166% from the average session volume of 709,477 shares. The stock had previously closed at GBX 868 ($10.97).
Analysts Set New Price Targets
Separately, Jefferies Financial Group restated a “buy” rating and set a GBX 1,800 ($22.74) price objective on shares of Indivior in a report on Tuesday, December 17th.
Read Our Latest Stock Report on INDV
Indivior Stock Performance
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Recommended Stories
- Five stocks we like better than Indivior
- Why Invest in High-Yield Dividend Stocks?
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- EV Stocks and How to Profit from Them
- DuPont’s Electronics Spinoff: The Start of Something Big
- What Are Some of the Best Large-Cap Stocks to Buy?
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.